Oncologist Provider Services
Actionable Information at Your Fingertips; Anywhere, Anytime
Overburdened? Overworked? Understaffed? Don’t have as much time to connect with your patients as you would like? Apricity Health is here to help.
ApricityCare is your virtual front desk and on-demand nurse triage. This service ensures high-touch patient engagement and real-time symptom management. This service frees you up to prioritize complex and new patient care, improve outcomes, and provide a better overall care experience.
ApricityCare is a 24/7 support structure provided by Oncology-trained nurses and backed by the ApricityRx patient monitoring platform – a secure and compliant (HIPAA & SOC2) digital health platform designed and developed with world renowned clinical experts.
Best of all, you are kept in the loop at all times. All encounter information between the Apricity Health nurse and your patient will be transmitted directly to your EHR via Direct Messaging. In addition, your staff will be contacted for any real-time escalation instances.
Interested in finding out more about how ApricityCare works, click on the link below, provide your contact information, and access the details on how the ApricityCare service can work for your patients.
Apricity Health Offers a Digital Solution Too
The ApricityCare service utilizes the ApricityOncology application. Your team will have access to this powerful software tool so you can have access to your patients in real-time just like the ApricityCare nurses. This tool connects you to your patients and helps you continually monitor their status for early detection and timely intervention. In addition, your staff will be informed of any real-time escalation instances.
You can use the daily patient-reported outcome data provided by this tool, in combination with the most relevant and up-to-date expert knowledge, to adjust and optimize your patient’s care.
Apricity Health MarketPlace
In addition to 24/7 nurse support, the ApricityCare offers access to a slew of healthcare partners who can provide supplemental services for you and your patients. Through the Apricity Health MarketPlace, you can request services such as Health & Beauty, Nutritional Consulting, Physical Therapy, Imaging, and a comprehensive Genomic profiling and testing service, to name a few.
Designed for Oncology Teams,
by Oncology Experts
Apricity Health Founders
Lynda Chin, MD, President, CEO and Co-Founder, is an elected member of the National Academy of Medicine, Dr. Chin is a renowned cancer genomic scientist and a leader in the application of technologies, AI/ML and big data in medicine.
Keith Flaherty, MD, Co-Founder, is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. As described in the more than 300 peer-reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma.
Padmanee Sharma, MD/PhD, Co-Founder, is a nationally and internationally renowned physician scientist whose research work is focused on investigating mechanisms and pathways within the immune system that facilitate tumor rejection, with subsequent clinical benefit, or elicit resistance to immune checkpoint therapy.
James Allison, PhD, is founding advisor and Chair of the Scientific Advisory Board. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which he shared with Dr. Tasuku Honjo, “for their discovery of cancer therapy by inhibition of negative immune Regulation.”
Apricity Health Advisors and Collaborators
Dr. Bhardwaj is Professor of Medicine and Urology, Director of Immunotherapy, Medical Director of the Vaccine and Cell Therapy Laboratory, and Co-Director of the Cancer Immunology Program at The Tisch Cancer Institute. Former chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research, she is editor for Cancer Immunology Research and Frontiers in Immunology, holds the Ward Coleman Chair in Cancer Research, and has made seminal contributions to human dendritic cell biology.
Dr. Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and Professor of Medicine at Harvard Medical School. He received his MD degree from Cornell University Medical College in 1992. Dr. Hodi completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and Medical Oncology training at Dana-Farber Cancer Institute where he joined the faculty in 1995.
Dr. Lacouture is an Associate Professor and the director of the Oncodermatology Program in the Dermatology Service at Memorial Sloan Kettering Cancer Center in New York City. He did his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL.
Dr. Mackall is an Endowed Professor of Pediatrics and Medicine at Stanford University. She is Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, and Director of the Parker Institute for Cancer Immunotherapy at Stanford.
Dr. Newcomer served as Chief Medical Director at UnitedHealth Group, Medical Director for Cigna Healthcare, founding executive of Vivius, and former Chairman of Park Nicollet Health Services. He completed a Masters of Health Administration from the University of Wisconsin, his residency at the University of Nebraska Medical Center, and a medical oncology fellowship at the Yale University School of Medicine. He earned a MD from the University of Nebraska College of Medicine, and a BA from Nebraska Wesleyan University.
Dr. Ribas is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA.
Dr. Subudhi is Assistant Professor, Genitourinary Medical Oncology, a medical oncologist and immunologist whose research focuses on the mechanisms and pathways within the immune system that are responsible for tumor rejection and clinical benefit. He earned a PhD in Biological Science from The University of Chicago Division of Biological Sciences, a MD at The University of Chicago Prizker School of Medicine, , and a BA in Biological Basis of Behavior from The University of Pennsylvania College of Arts and Sciences.
Dr. Wolchok is Chief of the Immuno-Oncology Service and holds The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK). He is also head of the Swim Across America – Ludwig Collaborative Laboratory; Associate Director of the Ludwig Center for Cancer Immunotherapy (LCCI); SU2C–ACS Lung Cancer Dream Team Co-leader and Director of the Parker Institute for Cancer Immunotherapy at MSK.